Back to Journals » OncoTargets and Therapy » Volume 13

Autophagy-Related Beclin 1 and Head and Neck Cancers

Authors Hu YJ, Zhong JT, Gong L, Zhang SC, Zhou SH

Received 30 March 2020

Accepted for publication 10 June 2020

Published 30 June 2020 Volume 2020:13 Pages 6213—6227

DOI https://doi.org/10.2147/OTT.S256072

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Carlos E Vigil


Yang-Jie Hu,1,2 Jiang-Tao Zhong,2 Liang Gong,1 Si-Cong Zhang,1 Shui-Hong Zhou2

1Department of Otolaryngology, The Affiliated Cixi Hospital of Wenzhou Medical University, Cixi 315300, Zhejiang, People’s Republic of China; 2Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, People’s Republic of China

Correspondence: Shui-Hong Zhou
Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou City 310003, People’s Republic of China
Tel +86-13868060120
Fax +86-571-87236895
Email 1190051@zju.edu.cn

Abstract: Beclin 1, a positive regulator of autophagy, behaves as a double-edged sword in tumorigenesis. Beclin 1 contributes to tumor suppression by removing defective or damaged organelles and other cellular components; however, its activity can also stimulate cancer initiation and progression. In head and neck cancer, Beclin 1 overexpression promotes autophagy, which limits DNA damage and chromosomal instability and increases necrosis and inflammation by impacting apoptotic and autophagic pathways. This paper reviews the relationship between Beclin 1, carcinogenesis and head and neck cancer prognosis.

Keywords: head and neck cancer, autophagy, Beclin 1, carcinogenesis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]